Archive for the 'Avastin' Category

Avastin news feed.

Phase III Clinical Trial for Nintedanib Discontinued After Yielding Negative Results

Disappointing results from the LUME-Phase III clinical trial regarding nintedanib is a setback for scientists and researchers who were hopeful they were on the brink of finding a new, first line treatment for those suffering from mesothelioma. Results from the Phase II clinical trial – published earlier this year – showed promise for the triple

more

Nintedanib May Surpass Bevacizumab as a More Effective Chemotherapy Treatment for Mesothelioma

In 2016, scientists and researchers were excited to begin Phase II of the clinical trial involving treating patients with malignant pleural mesothelioma with Nintedanib, a triple angiokinase inhibitor designed to hinder protein kinases in cancer cells and stop cancer cells from growing their own blood vessels. The LUME-Meso Phase II trial yielded promising results –

more

Bevacizumab – A Positive Treatment with Serious Side Effects

Bevacizumab (Avastin) is commonly viewed as chemotherapy treatment because when administered intravenously, it is particularly effective in controlling such illnesses such as lung cancer and colon cancer. However, it is a bit different than traditional chemotherapy treatments, which directly attack cancer cells. Bevacizumab fights cancer cells by cutting off oxygen and other nutrients the cells

more

Bevacizumab (Avastin): Part of a New Treatment Regimen for Mesothelioma Patients

The results of a 2016 Phase III trial of the monoclonal antibody bevacizumab (Avastin) have established another option for treatment for those suffering from malignant pleural mesothelioma. Angiogenesis, which is the formation of new blood vessels, plays a key role in mesothelioma because it allows the tumors and cancer to spread. However, scientists and researchers

more

Adding an inhibitor to mesothelioma treatment proves effective

A recent mesothelioma study found the addition of bevacizumab to the chemotherapy treatment of pemetrexed plus cisplatin may increase the survival rate in patients. From 2008 to 2014, patients were given the standard treatment in 21-day increments for six cycles, with some receiving bevacizumab. The addition of bevacizumab increased survival to a median of 19.8

more

Updated Analysis in Second-Line Treatment of Lung Cancer Trial Confirms Similar Survival for Alimta(R) and Docetaxel; Alimta Also Shows Tolerability as Triplet Combination Treatment in First-Line Lung Cancer

Data presented today at the 42nd American Society of Clinical Oncology (ASCO) annual meeting in Atlanta, Ga., affirms that ALIMTA® (pemetrexed), manufactured and marketed by Eli Lilly and Company, offers patients with advanced non-small cell lung cancer (NSCLC) similar overall survival as docetaxel (Taxotere®). The survival data were part of a large (n=571), randomized Phase

more

FDA Approves Avastin, A Targeted Therapy for First-Line Metastatic Colorectal Cancer Patients; First Anti-Angiogenesis Treatment Approved for Treating Cancer

Related News 2 drugs open a new front in cancer war: Avastin, Erbitux herald revolution that targets cells (free membership required) – March 2, 2004 (Judy Peres, Chicago Tribune). QUOTE:“‘We’re in a new era of drug development for cancer,’ said Dr. Hedy Kindler, director of gastrointestinal oncology at the University of Chicago who has tested

more

ERBITUX–Cetuximab–Receives FDA Approval to Treat Irinotecan Refractory or Intolerant Metastatic Colorectal Cancer; First-of-its-Kind Antibody Approved for Use in Combination with Irinotecan and As a Single Agent

Related News 2 drugs open a new front in cancer war: Avastin, Erbitux herald revolution that targets cells (free membership required) – March 2, 2004 (Judy Peres, Chicago Tribune). QUOTE:“‘We’re in a new era of drug development for cancer,’ said Dr. Hedy Kindler, director of gastrointestinal oncology at the University of Chicago who has tested

more

Last update: March 06, 2014. 08:41:31 pm.